Pharsight

Genentech Inc patents expiration

1. Cotellic patents expiration

COTELLIC's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7803839 GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Nov, 2029

(5 years from now)

US10478400 GENENTECH INC Immediate-release tablets containing combimetinib and methods of making and using the same
Jun, 2036

(12 years from now)

US10590102 GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone
Jun, 2036

(12 years from now)

US11254649 GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
Jun, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11597699 GENENTECH INC MEK inhibitors and methods of their use
Oct, 2026

(2 years from now)

US8362002 GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Oct, 2026

(2 years from now)

US8362002

(Pediatric)

GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Apr, 2027

(2 years from now)

US7803839

(Pediatric)

GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
May, 2030

(5 years from now)

US11087354 GENENTECH INC Combination therapies
Jun, 2034

(10 years from now)

US11087354

(Pediatric)

GENENTECH INC Combination therapies
Dec, 2034

(10 years from now)

US10478400

(Pediatric)

GENENTECH INC Immediate-release tablets containing combimetinib and methods of making and using the same
Dec, 2036

(12 years from now)

US11254649

(Pediatric)

GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
Dec, 2036

(12 years from now)

US10590102

(Pediatric)

GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone
Dec, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-902) Oct 28, 2025
M(M-278) Jul 28, 2025
Orphan Drug Exclusivity(ODE-416) Oct 28, 2029
Pediatric Exclusivity(PED) Jan 28, 2026
Orphan Drug Exclusivity(ODE-101) Nov 10, 2022
New Chemical Entity Exclusivity(NCE) Nov 10, 2020
Orphan Drug Exclusivity(ODE) Nov 10, 2022

Drugs and Companies using COBIMETINIB FUMARATE ingredient

NCE-1 date: 28 January, 2025

Market Authorisation Date: 10 November, 2015

Treatment: As a single agent for the treatment of adult patients with histiocytic neoplasms; Method of using cobimetinib for the treatment of melanoma

Dosage: TABLET;ORAL

More Information on Dosage

COTELLIC family patents

Family Patents

2. Esbriet patents expiration

ESBRIET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9561217 GENENTECH INC Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone
Jan, 2022

(2 years ago)

US8753679 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
Sep, 2026

(2 years from now)

US7988994 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
Sep, 2026

(2 years from now)

US7767225 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
Sep, 2026

(2 years from now)

US8420674 GENENTECH INC Method of providing pirfenidone therapy to a patient
Dec, 2027

(3 years from now)

US7767700 GENENTECH INC Method of providing pirfenidone therapy to a patient
Dec, 2027

(3 years from now)

US7696326 GENENTECH INC Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
Dec, 2027

(3 years from now)

US7696236 GENENTECH INC Method of providing pirfenidone therapy to a patient
Dec, 2027

(3 years from now)

US8383150 GENENTECH INC Granulate formulation of pirfenidone and pharmaceutically acceptable excipients
May, 2028

(3 years from now)

US7635707 GENENTECH INC Pirfenidone treatment for patients with atypical liver function
Apr, 2029

(4 years from now)

US8592462 GENENTECH INC Pirfenidone treatment for patients with atypical liver function
Apr, 2029

(4 years from now)

US7566729 GENENTECH INC Modifying pirfenidone treatment for patients with atypical liver function
Apr, 2029

(4 years from now)

US8609701 GENENTECH INC Pirfenidone treatment for patients with atypical liver function
Apr, 2029

(4 years from now)

US8318780 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(5 years from now)

US8013002 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(5 years from now)

US7910610 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(5 years from now)

US7816383 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(5 years from now)

US8754109 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450
Jan, 2030

(5 years from now)

US8084475 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450
Jan, 2030

(5 years from now)

US8648098 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450
Jan, 2030

(5 years from now)

US8778947 GENENTECH INC Methods of administering pirfenidone therapy
Aug, 2033

(9 years from now)

US10188637 GENENTECH INC Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same
Mar, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-77) Oct 15, 2021
New Chemical Entity Exclusivity(NCE) Oct 15, 2019
Orphan Drug Exclusivity(ODE) Oct 15, 2021

Drugs and Companies using PIRFENIDONE ingredient

NCE-1 date: 15 October, 2018

Market Authorisation Date: 11 January, 2017

Treatment: Method of administering pirfenidone capsules to treat a fibrotic condition; Pirfenidone dose escalation regimen for treatment of fibrosis as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for day...

Dosage: TABLET;ORAL

How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage

ESBRIET family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Evrysdi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9586955 GENENTECH INC Compounds for treating spinal muscular atrophy
Feb, 2033

(8 years from now)

US9969754 GENENTECH INC Compounds for treating spinal muscular atrophy
May, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11827646 GENENTECH INC Compounds for treating spinal muscular atrophy
Jan, 2036

(11 years from now)

US11534444 GENENTECH INC Treatment of SMA
Oct, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-334) Aug 07, 2027
New Chemical Entity Exclusivity(NCE) Aug 07, 2025
Orphan Drug Exclusivity(ODE-400) May 27, 2029
New Patient Population(NPP) May 27, 2025
M(M-270) Oct 03, 2026

Drugs and Companies using RISDIPLAM ingredient

NCE-1 date: 07 August, 2024

Market Authorisation Date: 07 August, 2020

Treatment: Treatment of spinal muscular atrophy

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

EVRYSDI family patents

Family Patents

4. Rozlytrek patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9029356 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(4 years from now)

US8299057 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Mar, 2029

(4 years from now)

US9085565 GENENTECH INC Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(8 years from now)

US10738037 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673893 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(4 years from now)

US9616059 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(4 years from now)

US9085558 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(4 years from now)

US9255087 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(4 years from now)

US9649306 GENENTECH INC Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(8 years from now)

US10231965 GENENTECH INC Molecules for administration to ROS1 mutant cancer cells
Feb, 2035

(10 years from now)

US10561651 GENENTECH INC Methods for treating neuroblastoma
Feb, 2035

(10 years from now)

US11091469 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(12 years from now)

US11253515 GENENTECH INC Pharmaceutical compositions and dosage forms
Jul, 2038

(14 years from now)

US10398693 GENENTECH INC Pharmaceutical compositions and dosage forms
Jul, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-265) Aug 15, 2026
New Chemical Entity Exclusivity(NCE) Aug 15, 2024
Orphan Drug Exclusivity(ODE-313) Aug 15, 2026
New Patient Population(NPP) Oct 20, 2026
Orphan Drug Exclusivity(ODE-448) Oct 20, 2030

Drugs and Companies using ENTRECTINIB ingredient

NCE-1 date: 16 August, 2023

Market Authorisation Date: 15 August, 2019

Treatment: Treatment of ros1-positive non-small cell lung cancer; Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of neuroblastomas that have a neurotrop...

Dosage: CAPSULE;ORAL

More Information on Dosage

ROZLYTREK family patents

Family Patents

5. Xofluza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8987441 GENENTECH INC Substituted polycyclic carbamoyl pyridone derivative prodrug
Sep, 2031

(7 years from now)

US10392406 GENENTECH INC Substituted polycyclic pyridone derivatives and prodrugs thereof
Apr, 2036

(11 years from now)

US10759814 GENENTECH INC Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
Aug, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9815835 GENENTECH INC Substituted polycyclic carbamolypyridone derivative
Jun, 2030

(5 years from now)

US8927710 GENENTECH INC Substituted polycyclic carbamoylpyridone derivative
May, 2031

(6 years from now)

US10633397 GENENTECH INC Substituted polycyclic pyridone derivatives and prodrugs thereof
Apr, 2036

(11 years from now)

US11306106 GENENTECH INC Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
Aug, 2037

(13 years from now)

US11261198 GENENTECH INC Process for preparing substituted polycyclic pyridone derivative and crystal thereof
Sep, 2038

(14 years from now)

US11925648 GENENTECH INC Solid dosage form having excellent stability
Apr, 2041

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 24, 2023
New Indication(I-811) Oct 16, 2022

Drugs and Companies using BALOXAVIR MARBOXIL ingredient

NCE-1 date: 24 October, 2022

Market Authorisation Date: 24 October, 2018

Treatment: Method for post-exposure prophylaxis of influenza

Dosage: TABLET;ORAL; FOR SUSPENSION;ORAL

How can I launch a generic of XOFLUZA before it's drug patent expiration?
More Information on Dosage

XOFLUZA family patents

Family Patents